Compare the Effectiveness of nVNS and TENS on Pain and Quality of Life in Patients of Migraine

Compare the Effectiveness of Non-invasive Vagus Nerve Stimulation (nVNS) and Non-invasive Transcutaneous Electrical Nerve Stimulation (TENS) on Pain and Quality of Life (QOL) in Patients of Migraine: a Randomized Control Trial

Migraine is a genetically influenced complex neurological disorder characterized by episodes of moderate-to-severe headaches, typically unilateral and frequently accompanied by nausea and heightened sensitivity to light and sound. The common type of migraine headaches is migraine without aura. Migraine has an approximate prevalence of 14.7%, making it the third most common disease in the world. This study aims to compare the effectiveness of non-invasive vagus nerve stimulation (nVNS) and non-invasive transcutaneous electrical nerve stimulation (TENS) in managing pain and improving quality of life (QOL) in patients with migraine.

Inclusion Criteria:

• People will be eligible for participation of 18-75 years of age.
• Participants are included with previous diagnosis of migraine with aura according to ICHD-3 beta criteria.
• Patients who had 15 headache days per month over the last 6 months will be included in this study.

Exclusion Criteria:

• Participants with a history of secondary headaches,
• aneurysms, brain tumors, significant head trauma
• substance abuse, cardiovascular or cerebrovascular disease
• uncontrolled hypertension, psychiatric disorders,
• pregnancy, steroid use, botulinum toxin injections in the past 6 months, or certain other medical conditions were excluded.
• individuals with excessive use of pain medications, recent preventive treatments, or previous surgeries and procedures related to migraines will not be eligible.